Novartis: showcases drug pipeline at R&D event
(CercleFinance.com) - Novartis has over 25 potential blockbusters in its pipeline, as the Swiss drugmaker presented its R&D day in London today.
The company has 60 projects in Phase 2 development stages, with more than 10 compounds having advanced into Phase 3 or pivotal trials each year in 2020 and 2021.
Over 90% are expected to be first-in-class or first-in-indication, it said.
The late stage pipeline has also Phase 3 readouts and launches on the horizon that will drive near- to mid-term growth, Novartis added.
The biopharmaceutical company in particular counts on significant near-term launches, including ofatumumab in relapsing multiple sclerosis, and canakinumab in lung cancer.
In addition, approximately 90 innovative new molecular entitie are currently emerging from its institute for biomedical research, the group said.
All these announcements pushed the shares 0.6% higher on the Zurich Stock Exchange on Thursday morning.
Note that Novartis has begun its 9.7 billion dollar tender offer to purchase all The Medicines Company's shares in cash.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The company has 60 projects in Phase 2 development stages, with more than 10 compounds having advanced into Phase 3 or pivotal trials each year in 2020 and 2021.
Over 90% are expected to be first-in-class or first-in-indication, it said.
The late stage pipeline has also Phase 3 readouts and launches on the horizon that will drive near- to mid-term growth, Novartis added.
The biopharmaceutical company in particular counts on significant near-term launches, including ofatumumab in relapsing multiple sclerosis, and canakinumab in lung cancer.
In addition, approximately 90 innovative new molecular entitie are currently emerging from its institute for biomedical research, the group said.
All these announcements pushed the shares 0.6% higher on the Zurich Stock Exchange on Thursday morning.
Note that Novartis has begun its 9.7 billion dollar tender offer to purchase all The Medicines Company's shares in cash.
Copyright (c) 2019 CercleFinance.com. All rights reserved.